key: cord-1040246-pajtdd2e
authors: Manian, Deepti Vellaichamy; Jensen, Chelsee; Theel, Elitza S.; Mills, John R.; Joshi, Avni
title: Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products
date: 2020-11-21
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2020.11.009
sha: d3d64747db98c6e6b9c39f5f457b4e0b730dcdfb
doc_id: 1040246
cord_uid: pajtdd2e

nan

Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products With the growing surges in coronavirus disease 2019 (COVID-19) cases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the globe, there has been a growing concern regarding its implications among patients with primary immune deficiency disorders (PIDs). Common variable immunodeficiency is a common PID characterized by a failure in B cell differentiation with defective immunoglobulin production, making the patients uniquely susceptible to recurrent infections. 1 Although current evidence suggests a higher risk for more severe disease in patients with both primary and secondary immune deficiency states, the exact burden of COVID-19 in these disease states is unknown. 2, 3 There are multiple diagnostic strategies to identify COVID-19 infection. Reverse transcriptionepolymerase chain reaction (RT -PCR) or antigen-based testing is used to detect an active infection, whereas serologic tests are useful to detect past infections. A positive antibody test result is suggestive of infection at some time in the past, but whether these antibodies are protective against SARS-CoV-2 reinfection is unclear. A negative antibody result may indicate remote or no previous infection with SARS-CoV-2; however, individuals may receive negative results if samples are collected too soon after infection or if the individual is incapable of mounting a humoral immune response, particularly in PIDs or secondary immunosuppressed states. Immunity against SARS-CoV-2 is multifaceted and not solely dependent on the antibody response, with some studies reporting that innate and cellmediated immunity may also play a substantial role in recovery and prevention of reinfection with SARS-CoV-2. 4, 5 Neutralizing antibodies are those that inhibit the virus from infecting other cells and are generally thought to play a direct role in protective immunity. However, not all antibodies are neutralizing, and currently, the US Food and Drug Administration has yet to grant emergency use authorization to assays that are capable of distinguishing between neutralizing and non-neutralizing antibodies.

Here, we report a case of a 59-year-old woman, weighing 71 kg with common variable immunodeficiency, who presented for a yearly follow-up visit. She has been maintained on supplemental immunoglobulin G (IgG) therapy with 10% immune globulin injection (Gamunex -C, Grifols, Los Angeles, California) at a dose of 35 g every 3 weeks. Per the institutional guidelines, she underwent SARS-CoV-2 testing as a prerequisite for pulmonary function testing on May 20, 2020. The patient received a negative test result for SARS-CoV-2 by RT-PCR and a positive test result for IgG class antibodies against the SARS-COV-2 spike protein. She used to work in the local school system but had been mostly homebound over the previous 2 months because of the statewide "shelter-in-place" recommendations. Her potential exposure to SARS-CoV-2 might have been through her adult son, who was a health care worker and had received positive test results for SARS-CoV-2 by means of RT-PCR in March 2020. She reported very limited interactions with him and adherence to physical distancing and universal masking recommendations. It was unclear whether the SARS-CoV-2 antibodies were de novo production or exogenous from her intravenous immunoglobulin (IVIG) infusions.

Therefore, additional SARS-CoV-2 antibody levels were tested around her IVIG infusion to assess for a trend. We tested her again before her next IVIG infusion on June 5, 2020, and post-IVIG infusion on June 8, 2020. To further assess whether her seropositivity was a result of the IVIG infusions she received, we tested 6 samples from different commercially available IgG products (Privigen [CSL Behring, King of Prussia, Pennsylvania], Hizentra [CSL Behring, King of Prussia, Pennsylvania], Gamunex-C, and Gammagard Liquid [Takeda, Lexington, Massachusetts]) for SARS-CoV-2 IgG antibodies. All 6 samples were positive when tested undiluted using the Euroimmun SARS-CoV-2 IgG enzyme-linked immunosorbent assay (Euroimmun, Lübeck, Germany). At a 1-to-101 dilution (the recommended dilution by the manufacturer for testing serum), 4 commercial IgG preparations were still positive, 2 were negative, and 1 indeterminate. We further sought to assess whether these antibodies were neutralizing and found that none of the IVIG products were positive for neutralizing antibodies ( Table 1) .

The IVIG solutions were pooled from 3000 to 10,000 donors, which contributed to a wide range of antibody specificities against various infectious agents. These included but were not limited to bacterial and viral pathogens, including those causing respiratory coronavirus infections that are ubiquitous, reflecting the cumulative exposure of the donor population to the environment. 6 The lead time for IVIG preparation is typically 6 to 9 months after donor collection pooling. Recently, antibodies against several antigens of common human beta coronaviruses in IVIG preparations have exhibited positive cross-reactivity with SARS-CoV-2 antigens. 7 Cohorts representing the general population have exhibited low seroprevalence even in COVID-19 hotspots, suggesting that these antibodies may not be long lasting or individuals have not yet seroconverted. A recent cohort study of 175 patients with clinically mild COVID-19 infection reported robust induction of SARS-CoV-2especific neutralizing antibodies in 94% of patients within 2 weeks of symptom onset. Of note, 10 of these patients recovered without developing detectable neutralizing antibodies, suggesting that other components of the serologic response and cellular immune response may play a role in convalescence. 8 The positive SARS-CoV-2 IgG antibody results with negative neutralizing antibodies found in commercial IgG preparations may signify cross-reacting antibodies or false reactivity owing to the presence of these antibodies in the IVIG or subcutaneous immunoglobulin samples or the differences in the analytical sensitivity between the assays.

Future studies should seek to explore whether patients receiving commercial IVIG therapy have a lower incidence of SARS-CoV-2 infections or milder disease courses when infected. In addition, the potential to use commercial IVIG in patients as a prophylactic or therapeutic strategy has been explored on a clinical trial basis. 9 In summary, the utility of SARS-CoV-2 antibody testing in patients with humoral immunodeficiency on IgG replacement therapy is uncleardour case highlighting the caveats of serologic testing for COVID-19. Our survey of several commercially available IgG products for SARS-CoV-2 antibodies reported the presence of cross-reacting antibodies, which may be non-neutralizing in nature. 

Adrenergic urticaria: a new form of stress-induced hives

Adrenergic urticaria in a patient with anti-double-stranded DNA antibodies

Adrenergic urticaria: review of the literature and proposed mechanism

DePold Hohler A. Dermatological manifestations of postural tachycardia syndrome are common and diverse

Adrenergic urticaria and adrenergic pruritus

Refractory case of adrenergic urticaria successfully treated with clotiazepam

An index case of a rare form of inducible urticaria successfully treated with omalizumab

Dupilumab in persistent asthma with elevated eosinophil levels

Common variable immunodeficiency

COVID-19 in immunocompromised hosts: what we know so far

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

SARS-CoV-2-reactive T cells in patients and healthy donors

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

The production processes and biological effects of intravenous immunoglobulin

Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series